Circulating Anti-cytolethal Distending Toxin B and Anti-vinculin Antibodies as Biomarkers in Community and Healthcare Populations With Functional Dyspepsia and Irritable Bowel Syndrome.


Journal

Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142

Informations de publication

Date de publication:
07 2019
Historique:
pubmed: 30 7 2019
medline: 1 9 2020
entrez: 30 7 2019
Statut: ppublish

Résumé

Anti-cytolethal distending toxin B (CdtB) and anti-vinculin antibodies have been proposed as biomarkers that discriminate irritable bowel syndrome (IBS) diarrhea from inflammatory bowel disease; however, it is unknown whether they can also discriminate patients with IBS and IBS subtypes and functional dyspepsia (FD) from healthy individuals in the general population. We aimed to determine whether anti-CdtB and anti-vinculin can discriminate IBS and FD from health and from organic gastrointestinal (GI) disease. Adults were enrolled from 2 Australian studies: (i) a random, population-based study (n = 331) with subjects diagnosed with IBS (n = 63) or FD (n = 61) by modified Rome III criteria or healthy control subjects (n = 246) who did not meet criteria for IBS and/or FD and (ii) an outpatient-based study with subjects diagnosed with IBS (n = 256) and/or FD (n = 55) or organic GI disease (n = 182) by an independent clinician. Serum levels of anti-CdtB/anti-vinculin antibodies were determined by enzyme-linked immunosorbent assay. There was a significantly higher mean value of anti-CdtB in FD vs healthy controls (mean = 2.46 [SD = 0.72] vs mean = 2.14 [SD = 0.77]; P = 0.005) and IBS/FD overlap vs healthy controls (mean = 2.47 [SD = 0.78] vs mean = 2.14 [SD = 0.77]; P = 0.02). There were no significant differences in anti-CdtB in IBS and FD outpatients or IBS/FD subgroups compared with patients with organic GI disease. In terms of anti-vinculin, there were no significant differences between IBS and FD and healthy controls or between IBS and FD and organic GI disease controls. We did not confirm that anti-CdtB/anti-vinculin discriminated IBS diarrhea from organic GI disease in Australian subjects. However, we did find higher anti-CdtB in FD and IBS/FD overlap vs healthy controls. Postinfectious FD may be more common than currently recognized.

Identifiants

pubmed: 31356481
doi: 10.14309/ctg.0000000000000064
pmc: PMC6708662
doi:

Substances chimiques

Antibodies 0
Bacterial Toxins 0
Biomarkers 0
VCL protein, human 0
cytolethal distending toxin 0
Vinculin 125361-02-6

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e00064

Références

Gastroenterology. 2005 Jul;129(1):98-104
pubmed: 16012939
Curr Treatm Opt Rheumatol. 2015 Mar 1;1(1):82-105
pubmed: 26005632
Aliment Pharmacol Ther. 2014 Feb;39(4):426-37
pubmed: 24387672
BMC Immunol. 2009 Sep 28;10:52
pubmed: 19785746
Dig Dis Sci. 2015 May;60(5):1195-205
pubmed: 25424202
Front Cell Infect Microbiol. 2016 Dec 05;6:168
pubmed: 27995094
Am J Gastroenterol. 2011 Jun;106(6):1089-98
pubmed: 21245834
Dig Dis Sci. 2017 Aug;62(8):1913-1922
pubmed: 28551709
Ann Clin Biochem. 1999 Nov;36 ( Pt 6):704-21
pubmed: 10586307
Gastroenterology. 2007 Mar;132(3):913-20
pubmed: 17383420
Clin Exp Gastroenterol. 2010;3:127-37
pubmed: 21694856
Am J Gastroenterol. 2000 Jan;95(1):67-71
pubmed: 10638561
Am J Gastroenterol. 2002 Sep;97(9):2290-9
pubmed: 12358247
Aliment Pharmacol Ther. 2014 Apr;39(8):767-79
pubmed: 24612362
Aliment Pharmacol Ther. 2009 Apr 15;29(8):834-42
pubmed: 19226291
Am J Gastroenterol. 2010 Aug;105(8):1835-42
pubmed: 20461070
Dig Dis Sci. 2017 Jun;62(6):1480-1485
pubmed: 28451914
Gastroenterology. 2014 May;146(6):1500-12
pubmed: 24583088
Gastroenterology. 2017 Apr;152(5):1042-1054.e1
pubmed: 28069350
Clin Gastroenterol Hepatol. 2007 Oct;5(10):1175-83
pubmed: 17686660
Gastroenterology. 2006 Apr;130(5):1480-91
pubmed: 16678561
Neurogastroenterol Motil. 2008 May;20 Suppl 1:121-9
pubmed: 18402649
J Gastroenterol Hepatol. 2011 Apr;26 Suppl 3:39-41
pubmed: 21443707
PLoS One. 2015 May 13;10(5):e0126438
pubmed: 25970536
Eur J Clin Invest. 2015 Dec;45(12):1350-9
pubmed: 26444549
Health Qual Life Outcomes. 2003 Aug 01;1:29
pubmed: 12914662
N Engl J Med. 2017 Jun 29;376(26):2566-2578
pubmed: 28657875
J Immunol Methods. 2009 Oct 31;350(1-2):125-32
pubmed: 19748508
Clin Chim Acta. 1986 Feb 28;155(1):69-76
pubmed: 3516456
J Neurogastroenterol Motil. 2010 Jan;16(1):30-4
pubmed: 20535323
Digestion. 2004;70(4):210-3
pubmed: 15627768
N Engl J Med. 2015 Nov 5;373(19):1853-63
pubmed: 26535514
Scand J Gastroenterol. 2005 Oct;40(10):1140-8
pubmed: 16265771

Auteurs

Marjorie M Walker (MM)

Faculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales, Australia.
Australian Gastrointestinal Research Alliance (AGIRA).

Grace Burns (G)

Faculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales, Australia.
Australian Gastrointestinal Research Alliance (AGIRA).

Michael Jones (M)

Australian Gastrointestinal Research Alliance (AGIRA).
Macquarie University, Ryde, New South Wales, Australia.

Natasha A Koloski (NA)

Faculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales, Australia.

Simon Keely (S)

Faculty of Health and Medicine, University of Newcastle, Callaghan, New South Wales, Australia.
Australian Gastrointestinal Research Alliance (AGIRA).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH